National Association of Epilepsy Centers

EQS-News: PRECISIS GmbH: EASEE – ­­­World's first minimally invasive brain pacemaker for the treatment of epilepsy receives CE-certification and is available immediately

Retrieved on: 
Friday, September 23, 2022

Heidelberg, 23.09.2022 after seven years of development work, Precisis GmbH, headquartered in Heidelberg, has received the CE certification for its minimally invasive brain pacemaker EASEE.

Key Points: 
  • Heidelberg, 23.09.2022 after seven years of development work, Precisis GmbH, headquartered in Heidelberg, has received the CE certification for its minimally invasive brain pacemaker EASEE.
  • These drug-refractory patients wait an average of 22 years before they are offered further technical or surgical treatment options.
  • With this new, risk-minimized EASEE method, the treatment spectrum is expanded in the early phases of the disease."
  • EASEE is an acronym for Epicranial Application of Stimulation Electrodes for Epilepsy.

Medical Marijuana, Inc. Subsidiary HempMeds® Collaborates With Leading Research Hospital in Argentina to Study the Efficiency of CBD for Adult Epilepsy

Retrieved on: 
Wednesday, July 6, 2022

The Ministry of Health of Argentina has authorized Hospital del Cruce, the leading research venue in Argentina, to import HempMeds products and execute the study.

Key Points: 
  • The Ministry of Health of Argentina has authorized Hospital del Cruce, the leading research venue in Argentina, to import HempMeds products and execute the study.
  • We have been involved in CBD research efforts in Latin America since 2017, collaborating with top medical doctors and organizations.
  • As a subsidiary of Medical Marijuana, Inc., HempMeds is the exclusive distributor for premium brands such as Real Scientific Hemp Oil.
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

MEGIN announces sale of TRIUX™ neo to University of Nebraska Medical Center

Retrieved on: 
Monday, March 14, 2022

HELSINKI, March 14, 2022 /PRNewswire/ --MEGIN is delighted to announce the purchase of our fourth-generation magnetoencephalography (MEG) technology, the TRIUX neo, by the University of Nebraska Medical Center (UNMC).

Key Points: 
  • HELSINKI, March 14, 2022 /PRNewswire/ --MEGIN is delighted to announce the purchase of our fourth-generation magnetoencephalography (MEG) technology, the TRIUX neo, by the University of Nebraska Medical Center (UNMC).
  • MEGIN's TRIUX neo is a highly sensitive technology that can accurately detect and localize neural events that are generated in the brain with exquisite resolution.
  • The TRIUX neo offers the most precise functional information currently available on the market for functional brain imaging in children, adolescents and adults.
  • Copyright 2022 MEGIN TRIUX neo is available for sale in the European Union, UK, Japan, Canada, the United States, as well as certain other countries.

MEGIN announces sale of TRIUX™ neo to University of Nebraska Medical Center

Retrieved on: 
Monday, March 14, 2022

HELSINKI, March 14, 2022 /PRNewswire/ --MEGIN is delighted to announce the purchase of our fourth-generation magnetoencephalography (MEG) technology, the TRIUX neo, by the University of Nebraska Medical Center (UNMC).

Key Points: 
  • HELSINKI, March 14, 2022 /PRNewswire/ --MEGIN is delighted to announce the purchase of our fourth-generation magnetoencephalography (MEG) technology, the TRIUX neo, by the University of Nebraska Medical Center (UNMC).
  • MEGIN's TRIUX neo is a highly sensitive technology that can accurately detect and localize neural events that are generated in the brain with exquisite resolution.
  • The TRIUX neo offers the most precise functional information currently available on the market for functional brain imaging in children, adolescents and adults.
  • Copyright 2022 MEGIN TRIUX neo is available for sale in the European Union, UK, Japan, Canada, the United States, as well as certain other countries.

NYU Langone Receives $8M NIH Grant to Develop State-of-Art Brain Implant to Study Epilepsy

Retrieved on: 
Thursday, February 17, 2022

There is so much more we will be able to learn about electrical activity in the brain."

Key Points: 
  • There is so much more we will be able to learn about electrical activity in the brain."
  • Prototypes were tested intraoperatively for a period of up to 30 minutes in dozens of patients at both Duke and NYU Langone.
  • Clinical trials using an FDA-approved monitoring implant are expected to begin at NYU Langone Health in 2023.
  • The funding award is from NIH's Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative, which is aimed at revolutionizing our understanding of the human brain.

Hoag Opens Center for Advanced Visualization and Immersive Therapeutics

Retrieved on: 
Friday, October 1, 2021

NEWPORT BEACH, Calif., Oct. 1, 2021 /PRNewswire/ --Already a nationally recognized leader in Experiential Reality (XR) technology, Hoag Memorial Hospital Presbyterian today announced the opening of the new Hoag Center for Advanced Visualization and Immersive Therapeutics inside Hoag's Pickup Family Neurosciences Institute Newport Beach campus.

Key Points: 
  • NEWPORT BEACH, Calif., Oct. 1, 2021 /PRNewswire/ --Already a nationally recognized leader in Experiential Reality (XR) technology, Hoag Memorial Hospital Presbyterian today announced the opening of the new Hoag Center for Advanced Visualization and Immersive Therapeutics inside Hoag's Pickup Family Neurosciences Institute Newport Beach campus.
  • Hoag will host the 2nd Annual Hoag Advances in Clinical Virtual Reality Symposium on Friday, October 1, 2021.
  • A preview of the new Hoag Center for Advanced Visualization and Immersive Therapeutics will be presented at this symposium.
  • Hoag has been recognized as a designated Level 4 Comprehensive Epilepsy Center by the National Association of Epilepsy Centers.